Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 9/20 | 0.46 |
| ▸ | NPC1 | O15118 | 7/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21564436 | 0.83 | LATS1 (0.43) | TSHRRAB9ANPC1SMN1; SMN2PKM | |
| SCHEMBL29890985 | 0.83 | LATS1 (0.43) | TSHRRAB9ANPC1SMN1; SMN2PKM | |
| SCHEMBL12932912 | 0.81 | NPC1 (0.49) | TSHRRAB9ANPC1TP53MAPK1 | |
| SCHEMBL1435912 | 0.76 | NPC1 (0.46) | TSHRRAB9ANPC1MAPK1SMN1; SMN2 | |
| SCHEMBL28546897 | 0.76 | RAB9A (0.43) | TSHRRAB9ANPC1TP53MAPK1 | |
| SCHEMBL29168041 | 0.75 | ALDH1A1 (0.39) | TSHRRAB9ANPC1TP53MAPK1 | |
| SCHEMBL23321251 | 0.74 | TSHR (0.59) | TSHRRAB9ANPC1SMN1; SMN2PKM | |
| SCHEMBL4479092 | 0.74 | TSHR (0.55) | TSHRRAB9ANPC1TP53MAPK1 | |
| SCHEMBL28543777 | 0.73 | RAB9A (0.40) | TSHRRAB9ANPC1TP53MAPK1 | |
| SCHEMBL17253048 | 0.73 | NPC1 (0.47) | TSHRRAB9ANPC1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| EP-3790871-A1 | FURIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019215341-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | TSHR 3953/4885RAB9A 352/4885NPC1 250/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | TSHR 3953/4885RAB9A 352/4885NPC1 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.